文献速递乳腺癌

β受体阻滞剂与晚期HER2阴性乳腺癌无进展生存期改善:ROSE/TRIO-012研究的回顾性分析

Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study.
PubMed 文献 · Ann Oncol · 2017-01-01

该回顾性分析基于ROSE/TRIO-012双盲多国III期试验,纳入1144例HER2阴性晚期乳腺癌患者,比较使用与未使用β受体阻滞剂(BB)患者的结局。BB使用与无进展生存期(PFS)显著改善相关(10.3 vs 8.3个月;HR 0.81;95%CI 0.66-0.99;P=0.038),三阴性乳腺癌(TNBC)亚组获益更明显(13.0 vs 5.2个月;HR 0.52;95%CI 0.34-0.79;P=0.002),总生存期(OS)、总缓解率(ORR)和临床获益率(CBR)无差异。

要点

  • BB使用与晚期HER2阴性乳腺癌PFS改善相关(10.3 vs 8.3个月;HR 0.81;P=0.038)。
  • TNBC亚组BB使用PFS获益更明显(13.0 vs 5.2个月;HR 0.52;P=0.002)。
  • OS、ORR和CBR在BB使用与未使用患者间无差异。

核心结论

  • 在该探索性分析中,BB使用与PFS显著改善相关,尤其在TNBC患者和既往未暴露于BB的患者中。

研究设计与样本

  • 回顾性分析ROSE/TRIO-012双盲、多国III期试验,该试验随机分配1144例HER2阴性晚期乳腺癌患者接受一线多西他赛联合雷莫芦单抗或安慰剂治疗。
  • 比较使用BB与未使用BB患者的PFS、OS、总缓解率和临床获益率。

主要发现

  • 153/1144(13%)患者使用BB;62%在入组前使用,38%在入组后开始使用。
  • BB治疗患者中位PFS长于未使用BB患者(10.3 vs 8.3个月;HR 0.81;95%CI 0.66-0.99;P=0.038)。
  • 仅在入组后使用BB的患者中位PFS更高(15.5 vs 8.3个月;P<0.001)。
  • TNBC亚组中,BB使用患者中位PFS为13.0个月,未使用BB患者为5.2个月(HR 0.52;95%CI 0.34-0.79;P=0.002)。
  • BB使用对PFS的获益独立于治疗中出现的高血压(P=0.476),但与治疗臂相关(P=0.037);BB与治疗臂交互作用检验不显著(P=0.276)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recent retrospective studies suggest that beta-adrenergic blocking drugs (BB) are associated with improved outcomes in patients with a range of cancers. Although limited and discordant data suggest that BB may increase overall survival (OS) in localized breast cancer (BC), there is no information on the effects of BB in women with advanced BC. PATIENTS AND METHODS: To explore the association between BB use and BC outcomes, we retrospectively reviewed ROSE/TRIO-012, a double-blinded, multinational phase III trial that randomized 1144 patients with HER2-negative advanced BC to first-line docetaxel in combination with ramucirumab or placebo. We compared progression-free survival (PFS), OS, overall response rate, and clinical benefit rate in patients who received BB to those who did not. RESULTS: 153/1144 (13%) patients received BB; 62% prior to enrolment and 38% began after enrolment. Median PFS in BB treated patients was longer than in patients who did not receive them (10.3 versus 8.3 months; HR 0.81; 95% CI 0.66-0.99; P = 0.038). Patients treated with BB only after enrolment had even higher median PFS (15.5 versus 8.3 months, P < 0.001). In the TNBC subset, median PFS was 13.0 months with BB, compared to 5.2 months without BB (HR 0.52; 95% CI 0.34-0.79; P = 0.002). The benefit of BB intake in PFS was independent of treatment-emergent hypertension (P = 0.476) but associated with treatment arm (P = 0.037). The test for interactions between BB and treatment arm was not significant (P = 0.276). No differences were seen in OS, overall response rate, or clinical benefit rate. A validation dataset analysis had consistent but less substantial improved outcomes for women with node positive operable breast cancer receiving BB in the BCIRG-005 trial. CONCLUSIONS: In this exploratory analysis, BB intake was associated with significant improvement in PFS, particularly in patients with TNBC and patients not previously exposed to BB. CLINICAL TRIAL NUMBER: NCT00703326.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Spera G, Fresco R, Fung H, et al. Beta blockers and improved progression-free survival in patients with advanced HER2 negative breast cancer: a retrospective analysis of the ROSE/TRIO-012 study. Ann Oncol. 2017. PMID: 28520849. doi:10.1093/annonc/mdx264

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。